

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Suresh K. Arya, Ph.D.

Application No. _____

Filed: Herewith

Confirmation No. _____

For: LENTIVIRUS VECTOR SYSTEM

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 4239-67517

MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
FOR CONTINUING APPLICATIONS

Listed on the accompanying form PTO-1449 are several English-language and/or non-English-language documents. Applicant respectfully requests that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/869,588, which was filed June 28, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicant in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicant will furnish the Patent Office with such copies upon request.

A copy Kaye et al., *J. Virol.* 73:3023-3031 (1999), which is listed on the accompanying form PTO-1449 and was cited by the Patent Office in the earlier application is enclosed.

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550.


A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-67517	App: _____
	Applicant: Suresh K. Arya, Ph.D.	
	Filed: 12/9/2003	Art Unit: _____

U.S. PATENT DOCUMENTS

Init.*		Number	Date	Name	Class	Sub	Filed
		5,162,215	11/10/1992	Bosselman et al.			
		5,656,465	8/12/1997	Panicali et al.			
		5,658,785	8/19/1997	Johnson			
		5,665,577	9/9/1997	Sodroski et al.			
		5,741,486	4/21/1998	Pathak et al.			
		5,747,307	5/5/1998	Lever et al.			
		5,747,324	5/5/1998	Mazzara et al.			

FOREIGN PATENT DOCUMENTS

		Number	Date	Country	Class	Sub	
		WO 95/25806	28.09.95	PCT			
		WO 96/37623	28.11.96	PCT			
		WO 97/36481	09.10.97	PCT			
		WO 98/39463	11.09.98	PCT			
		WO 98/51810	19.11.98	PCT			
		WO 99/61598	2.12.99	PCT			

OTHER DOCUMENTS

			Arya et al., "Human Immunodeficiency Virus Type 2 Lentivirus Vectors for Gene Transfer: Expression and Potential for Helper Virus-Free Packaging," <i>Hum. Gene Ther.</i> 9:1371-1380 (1998).
--	--	--	---

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Docket: 4239-59316	App: _____
			Applicant: Suresh K. Arya	
			Filed: Herewith	Art Unit: _____
OTHER DOCUMENTS				
			Blömer et al., "Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector," <i>J. Virol.</i> 71:6641-6649 (1997).	
			Borg et al., "Involvement of Human Immunodeficiency Virus Type-1 Splice Sites in the Cytoplasmic Accumulation of Viral RNA," <i>Virol.</i> 236:95-103 (1997).	
			Buchsacher, et al., "Development of Lentiviral Vectors for Gene Therapy for Human Diseases," <i>Blood</i> 8:2499-2504 (2000).	
			Clavel et al., "Molecular Cloning and Polymorphism of the Human Immune Deficiency Virus Type 2," <i>Nature</i> 324:691-695 (1986).	
			Corbeau et al., "Efficient Gene Transfer by a Human Immunodeficiency Virus Type 1 (HIV-1)-Derived Vector Utilizing a Stable HIV Packaging Cell Line," <i>Proc. Natl. Acad. Sci. USA</i> 93:14070-14075 (1996).	
			Corbeau et al., "Transduction of Human Macrophages Using a Stable HIV-1/HIV-2-Derived Gene Delivery System," <i>Gene Ther.</i> 5:99-104 (1998).	
			Dillon et al., "Function of the Human Immunodeficiency Virus Types 1 and 2 Rev Proteins is Dependent on Their Ability to Interact with a Structured Region Present in <i>env</i> Gene mRNA," <i>J. Virol.</i> 64:4428-4437 (1990).	
			Garzino-Demo et al., "Human Immunodeficiency Virus Type 2 (HIV-2): Packaging Signal and Associated Negative Regulatory Element," <i>Hum. Gene Ther.</i> 6:177-184 (1995).	
			Kafri et al., "Sustained Expression of Genes Delivered Directly into Liver and Muscle by Lentiviral Vectors," <i>Nature Gen.</i> 17:314-317 (1997).	
EXAMINER:			DATE	
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Docket: 4239-59316	App: _____
			Applicant: Suresh K. Arya	
			Filed: Herewith	Art Unit: _____
OTHER DOCUMENTS				
			Kaye et al., "Human Immunodeficiency Virus Types 1 and 2 Differ in the Predominant Mechanism Used for Selection of Genomic RNA for Encapsidation," <i>J. Virol.</i> 73:3023-3031 (1999).	
			Kumar et al., "Molecular Characterization of an Attenuated Human Immunodeficiency Virus Type 2 Isolate," <i>J. Virol.</i> 64:890-901 (1990).	
			McBride et al., "The Human Immunodeficiency Virus Type 1 Encapsidation Site is a Multipartite RNA Element Composed of Functional Hairpin Structures," <i>J. Virol.</i> 70:2963-2973 (1996).	
			McBride et al., "Efficient Encapsidation of Human Immunodeficiency Virus Type 1 Vectors and Further Characterization of <i>cis</i> Elements Required for Encapsidation," <i>J. Virol.</i> 71:4544-4554 (1997).	
			McCann et al., "Location of <i>cis</i> -Acting Signals Important for RNA Encapsidation in the Leader Sequence of Human Immunodeficiency Virus Type 2," <i>J. Virol.</i> 71:4133-4137 (1997).	
			Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," <i>Science</i> 272:263-267 (1996).	
			Parolin et al., "Use of <i>cis</i> - and <i>trans</i> -Acting Viral Regulatory Sequences to Improve Expression of Human Immunodeficiency Virus Vectors in Human Lymphocytes," <i>Virol.</i> 222:415-422 (1996).	
			Poeschla et al., "Identification of a Human Immunodeficiency Virus Type 2 (HIV-2) Encapsidation Determinant and Transduction of Nondividing Human Cells by HIV-2-Based Lentivirus Vectors," <i>J. Virol.</i> 72:6527-6536 (1998).	
			Poznansky et al., "Gene Transfer into Human Lymphocytes by a Defective Human Immunodeficiency Virus Type 1 Vector," <i>J. Virol.</i> 65:532-536 (1991).	
EXAMINER:			DATE	
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Docket: 4239-59316	App: _____
			Applicant: Suresh K. Arya	
			Filed: Herewith	Art Unit: _____
OTHER DOCUMENTS				
			Sadaie et al., "Towards Developing HIV-2 Lentivirus-Based Retroviral Vectors for Gene Therapy: Dual Gene Expression in the Context of HIV-2 LTR and Tat," <i>J. Med. Virol.</i> 54:118-128 (1998).	
			Zufferey et al., "Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery In Vivo," <i>Nature Biotech.</i> 15:871-875 (1997).	
			Genbank Accession No.: M15390.	
			Genbank Accession No.: NM_002985	
			Genbank Accession No.: AF105229	
EXAMINER:			DATE	
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.				